
Sage Therapeutics SAGE
Sage Therapeutics Long Term Debt Current | SAGE
Annual Long Term Debt Current Sage Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.32 M | 5.16 M | 7.64 M | 7.47 M | 8.66 M | 10.2 M | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.2 M | 1.32 M | 6.75 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
BioLineRx Ltd.
BLRX
|
234 K | $ 1.49 | -1.97 % | $ 3.67 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 1.59 | -2.76 % | $ 2.62 M | ||
|
Lineage Cell Therapeutics
LCTX
|
816 K | $ 1.13 | 8.17 % | $ 260 M | ||
|
Paratek Pharmaceuticals
PRTK
|
500 K | - | - | $ 121 M | ||
|
TCR2 Therapeutics
TCRR
|
21.8 M | - | - | $ 58.1 M | ||
|
C4 Therapeutics
CCCC
|
6.37 M | $ 2.9 | -3.5 % | $ 240 M | ||
|
Eli Lilly and Company
LLY
|
222 M | $ 1 437.4 | 0.36 % | $ 1.29 T | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
226 K | - | -14.27 % | $ 1.7 M | ||
|
Compugen Ltd.
CGEN
|
521 K | $ 2.09 | -0.24 % | $ 195 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
6.49 M | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
GeoVax Labs
GOVX
|
263 K | $ 2.13 | -20.4 % | $ 2.04 M | ||
|
Unity Biotechnology
UBX
|
3.83 M | - | -33.41 % | $ 3.37 M | ||
|
MediciNova
MNOV
|
194 K | $ 1.41 | 0.36 % | $ 69.2 M | ||
|
AVEO Pharmaceuticals
AVEO
|
11 K | - | - | $ 521 M | ||
|
Seelos Therapeutics
SEEL
|
15 K | - | -47.76 % | $ 6.27 M | ||
|
Celldex Therapeutics
CLDX
|
1.55 M | $ 30.18 | -1.53 % | $ 2 B | ||
|
Moderna
MRNA
|
17 M | $ 248.62 | -0.88 % | $ 96.7 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
814 K | $ 3.96 | 1.41 % | $ 48.3 M | ||
|
Kiromic BioPharma
KRBP
|
685 K | - | 6.61 % | $ 3.08 M | ||
|
Nektar Therapeutics
NKTR
|
20.5 M | $ 38.41 | 1.67 % | $ 648 M | ||
|
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | ||
|
CorMedix
CRMD
|
853 K | $ 5.31 | -2.23 % | $ 383 K | ||
|
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 45.39 | 0.53 % | $ 4.08 B | ||
|
Deciphera Pharmaceuticals
DCPH
|
3.5 M | - | - | $ 2.18 B | ||
|
Idera Pharmaceuticals
IDRA
|
234 K | - | -23.04 % | $ 26.6 M | ||
|
Tyme Technologies
TYME
|
37.3 K | - | 8.07 % | $ 54 M | ||
|
Verona Pharma plc
VRNA
|
1.12 M | - | - | $ 69.7 B | ||
|
Oramed Pharmaceuticals
ORMP
|
285 K | $ 4.1 | 3.27 % | $ 170 M | ||
|
Karuna Therapeutics
KRTX
|
2.84 M | - | - | $ 12.2 B | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Curis
CRIS
|
1.19 M | $ 0.59 | -9.62 % | $ 7.77 M | ||
|
Cyclerion Therapeutics
CYCN
|
3.29 M | $ 34.99 | 3.77 % | $ 147 M | ||
|
Fusion Pharmaceuticals
FUSN
|
4.16 M | - | - | $ 1.41 B | ||
|
Gritstone Oncology
GRTS
|
6.9 M | - | 0.42 % | $ 213 M | ||
|
Pfizer
PFE
|
330 M | $ 29.42 | 0.19 % | $ 167 B | ||
|
HOOKIPA Pharma
HOOK
|
552 K | - | -6.92 % | $ 79.4 M | ||
|
Guardion Health Sciences
GHSI
|
3.81 K | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
338 K | - | - | $ 109 M | ||
|
Monopar Therapeutics
MNPR
|
90.6 K | $ 71.83 | 0.07 % | $ 532 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Otonomy
OTIC
|
3.36 M | - | -1.96 % | $ 4.68 M | ||
|
Prothena Corporation plc
PRTA
|
2.89 M | $ 8.74 | 2.1 % | $ 470 M | ||
|
Exelixis
EXEL
|
27.9 M | $ 70.73 | 0.21 % | $ 19.2 B | ||
|
Aridis Pharmaceuticals
ARDS
|
538 K | - | 17.91 % | $ 11.1 M |